-
Tytuł:
-
Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
-
Autorzy:
-
Gupta M; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Tripathy JP; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Verma M; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Singh MP; Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Kaur R; Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Ratho RK; Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Kumar R; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
-
Źródło:
-
The Indian journal of medical research [Indian J Med Res] 2019 Mar; Vol. 149 (3), pp. 396-403.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: <2011- > : Mumbai : Medknow
Original Publication: New Delhi : Council Of Medical Research
-
MeSH Terms:
-
Seroepidemiologic Studies*
Measles/*epidemiology
Mumps/*epidemiology
Rubella/*epidemiology
Adolescent ; Antibodies, Viral/blood ; Child ; Child, Preschool ; Female ; Humans ; India/epidemiology ; Infant ; Male ; Measles/blood ; Measles/immunology ; Measles virus/pathogenicity ; Measles-Mumps-Rubella Vaccine/therapeutic use ; Mumps/blood ; Mumps/immunology ; Rubella/blood ; Rubella/immunology ; Rubella virus/pathogenicity ; Vaccination
-
References:
-
Vaccine. 2011 Apr 18;29(18):3419-23. (PMID: 21396902)
Bull World Health Organ. 1991;69(4):415-23. (PMID: 1934235)
Vaccine. 2012 Oct 19;30(47):6721-7. (PMID: 22634294)
East Mediterr Health J. 2009 May-Jun;15(3):516-25. (PMID: 19731767)
Indian Pediatr. 2015 Jun;52(6):505-14. (PMID: 26121728)
Vaccine. 2003 Jun 2;21(19-20):2580-8. (PMID: 12744894)
Wkly Epidemiol Rec. 2009 Aug 28;84(35):349-60. (PMID: 19714924)
J Ayub Med Coll Abbottabad. 2011 Jul-Sep;23(3):134-7. (PMID: 23272455)
Indian Pediatr. 2011 May;48(5):379-82. (PMID: 21654004)
Indian J Med Res. 2011 Sep;134:302-6. (PMID: 21985812)
Lancet Glob Health. 2019 Apr;7(4):e472-e481. (PMID: 30797735)
J Med Assoc Thai. 2011 Mar;94(3):309-15. (PMID: 21560838)
Aging Cell. 2015 Jun;14(3):309-21. (PMID: 25720438)
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15. (PMID: 25573105)
Int J Prev Med. 2018 Mar 09;9:31. (PMID: 29619155)
Hum Vaccin Immunother. 2013 Dec;9(12):2529-32. (PMID: 23928952)
J Infect Dis. 2012 Nov 15;206(10):1542-8. (PMID: 22966129)
Indian Pediatr. 2014 Nov;51(11):897-9. (PMID: 25432219)
Expert Opin Pharmacother. 2003 Aug;4(8):1215-25. (PMID: 12877632)
Indian Pediatr. 2014 Jun;51(6):441-3. (PMID: 24986275)
Eur J Public Health. 2006 Apr;16(2):137-42. (PMID: 16207728)
PLoS One. 2012;7(8):e42867. (PMID: 22880124)
Vaccine. 2004 Sep 28;22(29-30):4110-6. (PMID: 15364464)
-
Contributed Indexing:
-
Keywords: Antibodies - measles - mumps - rubella - seroprevalence - seroprotection
-
Substance Nomenclature:
-
0 (Antibodies, Viral)
0 (Measles-Mumps-Rubella Vaccine)
0 (rubella antibodies)
-
Entry Date(s):
-
Date Created: 20190629 Date Completed: 20200116 Latest Revision: 20200309
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC6607815
-
DOI:
-
10.4103/ijmr.IJMR_1453_17
-
PMID:
-
31249206
-
Background & Objectives: : Globally, there is an effort to eliminate the measles and control rubella as these diseases lead to considerable morbidity and mortality especially among under-five children and are important public health problems. This study was aimed to estimate the seroprevalence of measles, mumps and rubella (MMR) antibodies among children of age 5-10 yr in Chandigarh, north India, to provide evidence on prevalent immunity levels.
Methods: : This cross-sectional study was conducted in Chandigarh, among 196 randomly selected healthy children (5-10 yr), who received either one or two doses of measles or MMR combination vaccine. Socio-economic background and immunization history were recorded. Blood sample (2 ml) was collected to estimate the MMR IgG antibody titres by using ELISA kits.
Results: : Protective seroprevalence of MMR antibodies was 40.8, 75.5 and 86.2 per cent, respectively. The geometric mean titres of MMR IgG antibodies in the study children were 11.3, 50.6 and 54.3 international units (IU)/ ml, respectively. The proportion of seroprotected children for measles was significantly higher among those who had received two or more doses (46.4%) of measles vaccine compared to those who had received single dose (35.6%) (P <0.001). About 16 per cent of children had received single dose of MMR vaccine. Among these, 71.4 and 100 per cent were seroprotected against mumps and rubella, respectively.
Interpretation & Conclusions: : A large proportion of children aged 5-10 yr lacked protective immunity against measles (60%); about one-fourth (15-25%) were susceptible to infection with mumps and rubella virus. Mumps vaccination may be considered to be included in National Immunization Schedule for children with periodic serosurveillance.
Competing Interests: None
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.